Mantle Cell Lymphoma (MCL) Completed Phase 1 / 2 Trials for Ublituximab (DB11850)

Also known as: Lymphoma, Mantle-Cell / Mantle Cell Lymphoma / Mantle-Cell Lymphoma / Lymphoma, Mantle- Cell / Lymphoma, Mantle Cell / Mantle-Cell Lymphomas / B cell lymphoma / Centrocytic lymphoma / Mantle cell lymphoma NOS / Mantle cell lymphomas

IndicationStatusPhase
DBCOND0071979 (Mantle Cell Lymphoma (MCL))Completed1 / 2
clinicaltrials.gov IdentifierTitlePurposeDrugs
NCT01744912Ublituximab in Combination With Lenalidomide in Patients With B-Cell Lymphoid MalignanciesTreatment